Immunocore director receives 27,492 stock options
Immunocore Holdings plc director John Irving Bell received a grant of 27,492 share options.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Immunocore Holdings plc director John Irving Bell received a grant of 27,492 share options. Each option gives the right to buy one ordinary share at an exercise price of $28.52 and expires on May 26, 2036. According to the terms, the options vest at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting, provided he remains in continuous service until that vesting date. Following this award, he holds 27,492 derivative securities linked to ordinary shares.
Insider Trade Summary
Grant/Award: 27,492 shares
Grant/Award
1 txn
Insider
Bell John Irving
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (Right to Buy) | 27,492 | $0.00 | $0.00 |
Holdings After Transaction:
Share Option (Right to Buy) — 27,492 contracts (Direct)
Holdings Before and After:
Share Option (Right to Buy), 0 to 27,492 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
Options granted: 27,492 options
Exercise price: $28.52 per share
Expiration date: May 26, 2036
+3 more
6 metrics
Options granted
27,492 options
Share Option (Right to Buy) granted to director
Exercise price
$28.52 per share
Conversion or exercise price of options
Expiration date
May 26, 2036
Option grant expiration
Underlying shares
27,492 ordinary shares
Underlying security shares for the options
Post-transaction derivative holdings
27,492 options
Total derivative securities following grant
Vesting date condition
Earlier of May 27, 2027 or day before next AGM
Subject to continuous service through vesting date
Key Terms
Share Option (Right to Buy), Ordinary Shares, exercise price, expiration date, +2 more
6 terms
exercise price financial
"conversion_or_exercise_price: "28.5200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-05-26T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"The shares subject to the option award shall vest at the earlier of"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual general meeting financial
"the day immediately prior to the date of the Issuer's next annual general meeting"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Immunocore (IMCR) report for John Irving Bell?
Immunocore reported that director John Irving Bell received a grant of 27,492 share options. These options are a compensation award, not an open-market purchase, and give him the right to buy ordinary shares at a fixed exercise price if they vest.
What are the key terms of John Irving Bell’s new options at Immunocore (IMCR)?
John Irving Bell was granted 27,492 share options with an exercise price of $28.52 per ordinary share, expiring May 26, 2036. The options vest only if he continues serving the company through the specified vesting date conditions outlined in the grant.
When do John Irving Bell’s Immunocore (IMCR) options vest?
The options vest at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting. Vesting is conditional on his continuous service with the company through that date, meaning unvested options could be forfeited if service ends earlier.
Is John Irving Bell’s Immunocore (IMCR) Form 4 transaction a market purchase or sale?
The Form 4 shows a grant of share options as compensation, not a market trade. The transaction is coded as an acquisition of derivatives, with no cash purchase or share sale in the market, so it does not directly reflect open-market trading sentiment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
